Hvivo signs €7.3m contract to test cold virus treatment

Hvivo, the pharmaceutical services company formerly known as Open Orphan, has signed a contract worth £6.3 million (€7.3 million) to test a potential treatment for the common cold.

The contract, which is with an unnamed biotechnology client, is for a human challenge trial for an antiviral candidate to treat human rhinovirus (HRV), evaluating the effect on viral load, safety, tolerability and prophylactic antiviral activity. It will be carried out at the company’s new quarantine facilities in Canary Wharf.

More than 150 distinct types of HRV are currently known, but to date, no antiviral has been approved in the prevention or treatment of HRV infection. While many people with HRV suffer mild infection or are asymptomatic, the virus group is linked to the exacerbation of asthma and COPD.

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    hVIVO to hold AGM on 13 May 2024

    hVIVO plc (LON:HVO), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has confirmed that the Company’s Annual Report and Accounts for the year ended

    hVIVO plc

    Hvivo reports 44% Rise in earnings and Record Year in 2023

    Pharmaceutical services firm Hvivo, formerly Open Orphan, reported a 44pc rise in earnings in 2023 in a “record year across all financial and operational metrics.” Earnings before interest, taxes, depreciation and amortisation (Ebitda) increased to £13m

    hVIVO plc

    hVIVO Investor Conference

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,